Tom Iarocci, MD
Follower of cancer research since 2001. Advocate for those dealing with blood cancer and others in need of hope and healing.
Disclaimer: I do not control what appears in the "wrapper" around my articles.
Dr. Iarocci's professional career began at the American College of Radiology in Philadelphia. As a research associate, he studied patterns and trends in cancer treatment across the nation, meeting Radiation Oncologists from nearly all-50 states.
Clinical trials and surveys he worked on focused on blood cancers but also treatment planning and radiation therapy for malignancies of the breast, lung, cervix, and esophagus. His contributions to the Digital Mammographic Imaging Screening Trial were acknowledged in the New England Journal of Medicine article, "Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening."
An independent writing professional since 2007, Dr. Iarocci has authored and edited many health articles for websites including WebMD, Medscape, MedPage Today, and MDLinx.
By engaging clients in the pharmaceutical industry, he gained an understanding of the drug development pathway, an appreciation for brand management and online marketing, and in so doing, he developed a built-in way to keep current with the rapid changes in medicine and in hematology-oncology. In one of these collaborations, he spent two years covering leukemia, lymphomas and other blood cancers, with a special emphasis on bulky malignancies and the risk of tumor lysis syndrome.
Most recently as Chief Medical Adviser at SymptomFind, Dr. Iarocci enjoyed reaching a non-medical patient audience, taking technical, clinical topics and distilling them down into plain English. He also enjoys using social media to make connections with people from all different walks of life.
Dr. Iarocci received his MD from the University of Maryland School of Medicine in Baltimore. His master’s thesis was on antibiotic-resistant bacteria – specifically the kind that tend to cause bloodstream infections in bone marrow transplant patients and in people with decreased white blood cells due to chemotherapy.
During his clinical rotations and afterward, he became familiar with patient care in hematology and oncology, and recalls time spent in the bone marrow transplant unit. In addition to keeping up to date through project-based work for clients, he recently studied bioinformatics at Oregon Health and Science University.
There is still the opportunity for healing, even when a cure seems out-of-reach.